View from City Road: Justifiable concern about Wellcome
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Wellcome to the horror dome - at least, if you are a Wellcome shareholder. The consistency with which last year's worst-performing big drug stock has continued to disappoint should have John Robb, its chairman and chief executive, wishing he had succeeded in splitting the roles if only to have someone to share the brickbats.
The drug group would like to portray the market's reaction to its figures as irrational. Yet nervousness about Wellcome's prospects has a perfectly justifiable basis in concern over the prospects for sales of Zovirax and the lack of a compensating high-quality drug pipeline, especially now the future for Retrovir looks so uncertain.
What the City wanted but failed to receive was reassurance that last year's fall in Zovirax's sales growth from 17 per cent in the first half to 7 per cent in the second was a blip, not a trend.
While sales were up this year, a price hike in the US was largely responsible. Unfortunately for Wellcome, the trick is not repeatable; in 1995 SmithKline Beecham will have its competing Famciclovir on the market.
In the increasingly cut-throat world that is the US drug industry, margins will in any case come under pressure.
Mr Robb acknowledged as much when he indicated current trading margins of almost 33 per cent were probably unrepeatable, and the future range would probably be 28 to 32 per cent.
Analysts took that as a profit warning. Unless some good news is forthcoming soon about how the company plans to tackle the American market, shareholders should do the same.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments